Note that some links may require registration or subscription.
Johnson & Johnson is set to release trial results soon for its one-dose COVID-19 vaccine, but bulk manufacturing is reportedly two months behind the original schedule. (New York Times)
Nevertheless, the company’s chief science officer said it will meet its target of 1 billion doses by year-end. (Reuters)
The unofficial U.S. COVID-19 toll hit 23,078,350 cases and 384,784 deaths as of 8:00 a.m. ET Thursday — up 229,017 and 3,963, respectively, from this time yesterday.
Ohio State University researchers say they found a SARS-CoV-2 variant with the same mutation as the U.K. strain, but with other features suggesting it arose in the U.S.
COVID-19 is increasingly affecting children and young adults, with trends now matching those of adults. (Morbidity and Mortality Weekly Report)
Alexion Pharmaceuticals said it stopped enrollment in its phase III trial of ravulizumab (Ultomiris) in adults with severe COVID-19 on mechanical ventilation, due to lack of efficacy.
Big tech companies Microsoft, Oracle and Salesforce have joined the coalition to digitize individuals’ vaccine status. (New York Times)
Dollar General will pay employees to get the COVID-19 vaccine. (Wall Street Journal)
People with disabilities are at increased risk of dying from coronavirus, but state policies range widely on when they can get immunized. (Washington Post)
Two World Health Organization investigators, part of a team dispatched to China to probe SARS-CoV-2’s origins, were blocked from entry after they tested positive for coronavirus antibodies. (CNN)
Yankee Stadium may be the next sports venue in the U.S. to be turned into a mass vaccination site. (CNN)
Actor Bruce Willis acknowledged an “error in judgment” when he refused to wear a mask in a Los Angeles Rite-Aid pharmacy. (People)
In other news: